Valentina Volchkova

Dr. Valentina Volchkova


Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 1998 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
VVViktor Volchkov
Viktor Volchkov
HFHeinz Feldmann
Heinz Feldmann
VVValentina Volchkova
Valentina Volchkova
HKHans-Dieter Klenk
Hans-Dieter Klenk
In the present study, we have investigated processing and maturation of the envelope glycoprotein (GP) of Ebola virus. When GP expressed from vaccinia virus vectors was analyzed by pulse–chase experiments, the mature form and two different precursors were identified. First, the endoplasmic reticulum form preGP er , full-length GP with oligomannosidic N -glycans, was detected. preGP er (110 kDa) was replaced by the Golgi-specific form preGP (160 kDa), full-length GP containing mature carbohydrates. preGP was finally converted by proteolysis into mature GP 1,2 , which consisted of two disulfide-linked cleavage products, the amino-terminal 140-kDa fragment GP 1 , and the carboxyl-terminal 26-kDa fragment GP 2 . GP 1,2 was also identified in Ebola virions. Studies employing site-directed mutagenesis revealed that GP was cleaved at a multibasic amino acid motif located at positions 497 to 501 of the ORF. Cleavage was blocked by a peptidyl chloromethylketone containing such a motif. GP is cleaved by the proprotein convertase furin. This was indicated by the observation that cleavage did not occur when GP was expressed in furin-defective LoVo cells but that it was restored in these cells by vector-expressed furin. The Reston subtype, which differs from all other Ebola viruses by its low human pathogenicity, has a reduced cleavability due to a mutation at the cleavage site. As a result of these observations, it should now be considered that proteolytic processing of GP may be an important determinant for the pathogenicity of Ebola virus.

1 December 1995 in Virology
Verified
Journal Article
Closed access
VVViktor Volchkov
Viktor Volchkov
SBStephan Becker
Stephan Becker
VVValentina Volchkova
Valentina Volchkova
Vladimir A. TernovoiVladimir A. Ternovoi
Vladimir A. Ternovoi
AKAleksandr N. Kotov
Aleksandr N. Kotov
HKHans-Dieter Klenk
Hans-Dieter Klenk

9 March 2001 in Science
Verified
Journal Article
Closed access
PDF file
VVViktor Volchkov
Viktor Volchkov
VVValentina Volchkova
Valentina Volchkova
Elke MühlbergerElke Mühlberger
Elke Mühlberger
LKLarissa V. Kolesnikova
Larissa V. Kolesnikova
MWMichael Weik
Michael Weik
HKHans-Dieter Klenk
Hans-Dieter Klenk
To study the mechanisms underlying the high pathogenicity of Ebola virus, we have established a system that allows the recovery of infectious virus from cloned cDNA and thus permits genetic manipulation. We created a mutant in which the editing site of the gene encoding envelope glycoprotein (GP) was eliminated. This mutant no longer expressed the nonstructural glycoprotein sGP. Synthesis of GP increased, but most of it accumulated in the endoplasmic reticulum as immature precursor. The mutant was significantly more cytotoxic than wild-type virus, indicating that cytotoxicity caused by GP is down-regulated by the virus through transcriptional RNA editing and expression of sGP.

20 November 2014 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
Beatriz Escudero-PérezBeatriz Escudero-Pérez
Beatriz Escudero-Pérez
VVValentina Volchkova
Valentina Volchkova
ODOlga Dolnik
Olga Dolnik
PLPhilip Lawrence
Philip Lawrence
VVViktor Volchkov
Viktor Volchkov
During Ebola virus (EBOV) infection a significant amount of surface glycoprotein GP is shed from infected cells in a soluble form due to cleavage by cellular metalloprotease TACE. Shed GP and non-structural secreted glycoprotein sGP, both expressed from the same GP gene, have been detected in the blood of human patients and experimentally infected animals. In this study we demonstrate that shed GP could play a particular role during EBOV infection. In effect it binds and activates non-infected dendritic cells and macrophages inducing the secretion of pro- and anti-inflammatory cytokines (TNFα, IL1β, IL6, IL8, IL12p40, and IL1-RA, IL10). Activation of these cells by shed GP correlates with the increase in surface expression of co-stimulatory molecules CD40, CD80, CD83 and CD86. Contrary to shed GP, secreted sGP activates neither DC nor macrophages while it could bind DCs. In this study, we show that shed GP activity is likely mediated through cellular toll-like receptor 4 (TLR4) and is dependent on GP glycosylation. Treatment of cells with anti-TLR4 antibody completely abolishes shed GP-induced activation of cells. We also demonstrate that shed GP activity is negated upon addition of mannose-binding sera lectin MBL, a molecule known to interact with sugar arrays present on the surface of different microorganisms. Furthermore, we highlight the ability of shed GP to affect endothelial cell function both directly and indirectly, demonstrating the interplay between shed GP, systemic cytokine release and increased vascular permeability. In conclusion, shed GP released from virus-infected cells could activate non-infected DCs and macrophages causing the massive release of pro- and anti-inflammatory cytokines and effect vascular permeability. These activities could be at the heart of the excessive and dysregulated inflammatory host reactions to infection and thus contribute to high virus pathogenicity. Ebola virus, a member of the Filoviridae family, causes lethal hemorrhagic fever in man and primates, displaying up to 90% mortality rates. Viral infection is typified by an excessive systemic inflammatory response resembling septic shock. It also damages endothelial cells and creates difficulty in coagulation, ultimately leading to haemorrhaging, organ failure and death. A unique feature of EBOV is that following infection high amounts of truncated surface GP, named shed GP, are released from infected cells and are detected in the blood of patients and experimentally infected animals. However the role of shed GP in virus replication and pathogenicity is not yet clearly defined. Here we show that shed GP released from virus-infected cells binds and activates non-infected DCs and macrophages causing the massive release of pro- and anti-inflammatory cytokines and also affects vascular permeability. These activities could be at the heart of the excessive and dysregulated inflammatory host reactions to infection and thus contribute to high virus pathogenicity.

22 April 2004 in The EMBO Journal
Verified
Journal Article
Closed access
PDF file
ODOlga Dolnik
Olga Dolnik
VVValentina Volchkova
Valentina Volchkova
WGWolfgang Garten
Wolfgang Garten
CCCaroline Carbonnelle
Caroline Carbonnelle
SBStephan Becker
Stephan Becker
VVViktor Volchkov
Viktor Volchkov

1 November 2000 in Virology
Verified
Journal Article
Closed access
VVViktor Volchkov
Viktor Volchkov
ACAleksandr A. Chepurnov
Aleksandr A. Chepurnov
VVValentina Volchkova
Valentina Volchkova
Vladimir A. TernovoiVladimir A. Ternovoi
Vladimir A. Ternovoi
HKHans-Dieter Klenk
Hans-Dieter Klenk